Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:22:55 EDT Tue 09 Jun 2026
Enter Symbol
or Name
USA
CA



Q:ACET - ADICET BIO INC - http://www.aceto.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ACET - Q0.27.00·9.200.17.22-0.04-0.653.93511,2207.46  7.46  7.126817.4384  6.0118:24:26May 1415 min RT 2¢

Recent Trades - Last 10 of 1220
Time ETExPriceChangeVolume
18:24:26Q7.06-0.20101
18:19:13Q7.15-0.11150
18:18:04Q7.15-0.1112
16:10:04Q7.22-0.041
16:10:04Q7.22-0.041
16:10:03Q7.22-0.041
16:10:03Q7.22-0.041
16:06:21Q7.05-0.211
16:04:51Q7.22-0.041
16:04:50Q7.22-0.041

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-05-14 16:00U:ACETNews ReleaseAdicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference
2026-05-13 16:01U:ACETNews ReleaseAdicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-03-12 16:00U:ACETNews ReleaseAdicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
2026-01-30 07:00U:ACETNews ReleaseAdicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
2026-01-07 07:00U:ACETNews ReleaseAdicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones
2025-12-26 08:30U:ACETNews ReleaseAdicet Bio Announces Reverse Stock Split
2025-11-28 14:23U:ACETNews ReleaseAdicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
2025-11-05 16:01U:ACETNews ReleaseAdicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
2025-10-31 16:59U:ACETNews ReleaseAdicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2025-10-28 07:00U:ACETNews ReleaseAdicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference
2025-10-16 07:00U:ACETNews ReleaseAdicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)
2025-10-07 07:01U:ACETNews ReleaseAdicet Bio, Inc. Announces $80 Million Registered Direct Offering
2025-10-07 06:45U:ACETNews ReleaseAdicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)
2025-09-30 16:27U:ACETNews ReleaseAdicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
2025-09-02 07:00U:ACETNews ReleaseAdicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference
2025-08-29 16:48U:ACETNews ReleaseAdicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2025-08-07 16:01U:ACETNews ReleaseAdicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates
2025-08-05 07:00U:ACETNews ReleaseAdicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference
2025-07-24 07:00U:ACETNews ReleaseAdicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases